

PROTOCOL CODE: LYDARCBDF

(Page 1 of 3)

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE:	To be given:	Cycle #:		
Date of Previous Cycle: _____				
****Ensure Red Blood Cell Phenotype and Group and Screen for all patients prior to Cycle 1****				
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff day of treatment				
Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: ANC greater than or equal to 1.0 x 10⁹/L, platelets greater than or equal to 50 x 10⁹/L, total bilirubin less than or equal to 1.5 x upper limit of normal, and eGFR or creatinine clearance per protocol				
Dose modification for: <input type="checkbox"/> Hematology: _____ <input type="checkbox"/> Other Toxicity: _____				
Proceed with treatment based on blood work from _____				
CYCLOPHOSPHAMIDE – Cycles 1 to 6				
<input type="checkbox"/> cyclophosphamide 500 mg PO once weekly in the morning on Days 1, 8, 15 and 22. Dispense _____ cycles. OR <input type="checkbox"/> cyclophosphamide _____ mg PO once weekly in the morning on Days _____ Dispense _____ cycles. OR <input type="checkbox"/> cyclophosphamide 50 mg PO once in the morning every 2 days for _____ doses. Dispense _____ cycles				
BORTEZOMIB – Cycles 1 to 6				
• Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily				
bortezomib <input type="checkbox"/> 1.5 mg/m ² <input type="checkbox"/> 1.3 mg/m ² or <input type="checkbox"/> 1 mg/m ² or <input type="checkbox"/> 0.7 mg/m ² or <input type="checkbox"/> 0.5 mg/m ² (select one) x BSA = _____ mg subcutaneous injection weekly on Days 1, 8, 15, and 22				
STEROID (select one)* RN to use patient's therapeutic steroid as pre-med for daratumumab				
Cycles 1 to 6				
<input type="checkbox"/> dexamethasone <input type="checkbox"/> 40 mg or <input type="checkbox"/> 20 mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR <input type="checkbox"/> dexamethasone _____ mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, OR <input type="checkbox"/> predniSONE _____ mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning <input type="checkbox"/> No steroid				
*Refer to Protocol for suggested dosing options				
DOCTOR'S SIGNATURE:			SIGNATURE: UC:	

PROTOCOL CODE: LYDARCBDF

(Page 2 of 3)

DATE:

****Have Hypersensitivity Reaction Tray and Protocol Available****

Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event of a hypersensitivity reaction.

DARATUMUMAB

- Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily

DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm.

dexamethasone as ordered in steroid section

montelukast 10 mg PO prior to daratumumab on Cycle 1 Day 1

☐ **montelukast 10 mg** PO prior to each daratumumab

acetaminophen 650 mg PO prior to each daratumumab. Repeat **acetaminophen 650 mg** PO every 4 hours when needed

Select one of the following:

☐ **loratadine 10 mg** PO prior to each daratumumab, then **diphenhydrAMINE 50 mg** IV every 4 hours when needed

OR

☐ **diphenhydrAMINE 50 mg** ☐ PO or ☐ IV prior to each daratumumab. Repeat **diphenhydrAMINE 50 mg** IV every 4 hours when needed

DARATUMUMAB

☐ **CYCLE 1, Days 1, 8, 15 and 22:**

daratumumab subcut 1800 mg (fixed dose in 15 mL) **subcutaneously** into abdomen over 5 minutes*

☐ **CYCLE 2, Days 1, 8, 15 and 22:**

daratumumab subcut 1800 mg (fixed dose in 15 mL) **subcutaneously** into abdomen over 5 minutes*

☐ **CYCLES 3 to 6, Days 1 and 15:**

daratumumab subcut 1800 mg (fixed dose in 15 mL) **subcutaneously** into abdomen over 5 minutes*

☐ **CYCLES 7 onwards, Day 1:**

daratumumab subcut 1800 mg (fixed dose in 15 mL) **subcutaneously** into abdomen over 5 minutes*

x ____ cycle(s) (max 3 cycles)

*Observe patient for 1 hour after administration on Day 1 of Cycle 1 only. For patients switching from IV daratumumab, observe for 30 minutes after the first subcutaneous dose. Observation not required on subsequent doses unless requested by physician. Vital signs immediately prior to and at the end of injection, and at end of observation period of first injection only, and as needed.

NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at alternative injection sites whenever possible.

DOCTOR'S SIGNATURE:

SIGNATURE:

UC:

PROTOCOL CODE: LYDARCBDF

(Page 3 of 3)

DATE:
RETURN APPOINTMENT ORDERS

For Cycles 1 to 6 book chemo on Days 1, 8, 15, 22

For Cycles 7 and subsequent, book chemo on Day 1

- ☐ Return in **four** weeks for Doctor and Cycle _____
- ☐ Return in **eight** weeks for Doctor and Cycles _____ and _____. Book chemo x 2 cycles.
- ☐ Return in **twelve** weeks for Doctor and Cycles _____, _____ and _____. Book chemo x 3 cycles
- ☐ Last Cycle. Return in _____ week(s).

CBC & Diff, platelets, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels, troponin I cardiac high sensitivity, NT-pro BNP, albumin creatinine ratio urine every 4 weeks

- ☐ Urine protein electrophoresis every 4 weeks
- ☐ Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks
- ☐ Beta-2 microglobulin every 4 weeks
- ☐ CBC & Diff, platelets Days 8, 15, 22
- ☐ Creatinine, sodium, potassium Days 8, 15, 22
- ☐ Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22
- ☐ Random glucose Days 8, 15, 22
- ☐ Calcium, albumin Days 8, 15, 22
- ☐ **HBV viral load**
- ☐ Other tests:
- ☐ Consults:
- ☐ See general orders sheet for additional requests

DOCTOR'S SIGNATURE:
SIGNATURE:
UC: